Physician profile
Thomas E Gayer
NPI 1275624751
$1,646.76
in general payments reported to CMS, 2019-2025
13 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $35.19 · 2021: $181 · 2022: $183 · 2023: $210 · 2024: $387 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $452.81 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Allergan, INC. | $231.57 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $199.60 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $153.02 | 2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Bausch & Lomb Americas INC. | $138.02 | 2024 | Xiidra, Miebo, Alden Scleral Zenlens |
| Kala Pharmaceuticals, INC. | $121.90 | 2021 | |
| Alcon Vision LLC | $115.58 | 2023-2025 | Precision 1, Total30, Dailies Total1 |
| Johnson & Johnson Vision Care, INC. | $65.63 | 2023-2024 | Acuvue |
| Harrow Eye, LLC | $61.78 | 2024 | |
| Rxsight INC | $34.66 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Dompe US, INC. | $31.96 | 2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $20.89 | 2023 | Syfovre |
| Astellas Pharma US INC | $19.34 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.